Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GPH19 + GPH164
- Development stage
- Preclinical
- Lead developer
- Pauls Stradins Clinical University Hospital
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Parenteral, Topical
01
Overview
GPH19 + GPH164 is a bacteriophage cocktail consisting of two lytic phages, GPH19 (a *Przondovirus*) and GPH164 (a *Teetrevirus*), originating from the Geneva phage (GENPH) collection at the University Hospital of Geneva. This combination therapy is designed to target multidrug-resistant (MDR) *Klebsiella pneumoniae* strains. It has been evaluated for local and systemic administration (e.g., via intramedullary catheter) in combination with antibiotics for the treatment of MDR *Klebsiella pneumoniae* osteomyelitis.
- Other names
- GPH19 and GPH164GPH-19 and GPH164GPH 19 and GPH164GPH19/GPH164
Beyond the preview
Go deeper on GPH19 + GPH164.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GPH19 + GPH164.